Conference Day Two | Thursday, October 17

8:00 am Morning Networking Coffee

8:50 am Chair’s Opening Remarks

Overcoming TGF-β Therapeutic Toxicity by Design, Dosage & Delivery to Achieve Better Clinical Results

9:00 am Defeating the Highly Potent Toxicity of ADCs Targeting TGF-β for Effective Patient Response


  • Evolving the ALK5 inhibitor payload to achieve patient treatment success
  • Targeting TGF-β receptors using ADC to avoid toxicity in the heart and bone
  • Avoiding systematic toxicity in TGF-β directed therapies by highly specific targeting for better patient response

9:30 am Reimagining Precision Delivery to Enable TGF-β Therapies at Ultra-Low, Nontoxic Doses

  • Jan Schnitzer Founder, Chief Executive Officer & Institute Director, Proteogenomics Research Institute For Systems Medicine


  • Proving how endothelium is the critical barrier to low dose precision therapeutic efficacy without toxicities
  • New dual precision therapeutics to penetrate endothelium and to fully block TGF-β only inside the lung
  • Transvascular pumping of drugs by design boosts site delivery and potency 1000x and circumnavigates toxicity

New Data!

10:00 am Morning Networking Break & Poster Session


Contribute to the conversation and share your cutting-edge research with your fellow TGF-β community to showcase your breakthrough discoveries to a vast audience of experts. Register your place to submit an abstract for review to showcase your poster*

*Please visit the website for the T&Cs for presenting a poster

Employing Improved Animal Models in the Development of TGF-β Directed Therapies for Better Translation

11:00 am Overcoming Problems with Animal Models by Exploring GEM-Derived Allograft Models to Improve Translational Success


  • Exploring models to mimic tumor stroma in animal models to have a more accurate picture of human tumors
  • Developing genetically engineered model (GEM)-derived allografts to recapitulate stromal contexture of solid tumors
  • Modeling cold solid tumors in mice for preclinical evaluation of immunotherapy combinations

11:30 am Employing Small Molecule Design as a Safeguard Against Toxicity of TGF-β Targeted Therapies

  • Natalia Blanco Associate Director - Immuno-Oncology, Morphic Therapeutics


  • Targeting TGF-β activation to reduce unwanted side effects
  • Making treatments directed to TGF-β safe and efficacious by stimulating T cell responses and reducing fibrosis
  • Exploring response of αvβ8 inhibitor in mouse tumor models

12:00 pm Networking Lunch

Investigating Approaches to Improve Translation from Animals to the Clinic for TGF-β Directed Therapies

1:00 pm Selective Targeting GARP–TGF-β1 Increases Antitumor Activity by Remodeling the Immunosuppressive Tumor Microenvironment

  • Jack Chen Scientific Director - IO Translational Research Group Lead, Precision Medicine, Abbvie


  • Developing superior translational models for more accurate representation of patient tumors
  • Elucidating the mechanism-of-action by analyzing the tumor microenvironment pre- and post-treatment
  • Exploring biomarkers associated with improved results in the combination setting with anti-PD1

1:30 pm Roundtable Discussion: Boosting Clinical Efficacy by Using Alternative & Novel Models for Better Transition to the Clinic

  • Vaishali Shinde Senior Director - Translational & Clinical Assay Lead, Corbus Pharmaceuticals


  • Harnessing innovative models to improve translation from animals to humans
  • Exploring organoid alternatives to animals that can show more accurate response to TGF-β targeted therapies
  • Pioneering novel human cell models to follow a patients’ response to all therapies for better understanding of effective TGF-β targeted therapies

2:00 pm Afternoon Networking Break

Unlocking Alternative Modalities to Direct TGF-β Therapies with Low Immunogenicity & Better Therapeutic Effiacy

2:45 pm Developing a Novel Small Molecule Oxysterol as a Potent Inhibitor of TGF-β


  • Utilizing Oxy210 as a poly-pharmacological drug candidate to target 3 main signaling pathways in fibroblasts and other cells involved in fibrosis and inflammation
  • Demonstrating the intact TGF-β-mediated immune cell responses upon Oxy210 treatment
  • Evaluating the therapeutic effects of Oxy210 on chronic inflammatory diseases associated with metabolic dysfunction

New Data!

3:15 pm Using Oncolytic Viruses to Target TGF-β in the Tumor Microenvironment

  • Steve Thorne Chief Scientific Officer, KaliVir Immunotherapeutics


  • Directly targeting tumors using OVs to avoid systematic toxicity for better patient response
  • Targeting the TGF-β receptors with oncolytic viruses for strong immune response
  • Uncovering preclinical success using OVs to show clinical efficacy

New Data!

3:45 pm Chair’s Closing Remarks

4:00 pm End of 4th TGF-β Targeted Drug Development Summit 2024